226259-30-9

Basic information

• Product Name: Methyl 3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate
• Synonyms: Methyl 3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate;METHYL 3,4-DIHYDRO-2H-BENZO[B][1,4]THIAZINE-6-CARBOXYLATE
• CAS NO: 226259-30-9
• Molecular Formula: C10H11NO2S
• Molecular Weight: 209.26484
• Mol File: 226259-30-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 142-143°
• Boiling Point: 363.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.233±0.06 g/cm3(Predicted)
• PKA: 2.91±0.20(Predicted)
• CAS DataBase Reference: Methyl 3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate(226259-30-9)
• EPA Substance Registry System: Methyl 3,4-dihydro-2H-1,4-benzothiazine-6-carboxylate(226259-30-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 226259-30-9(Hazardous Substances Data)

Upstream product

• 188614-01-9 methyl 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 188614-00-8 methyl 4-((2-ethoxy-2-oxoethyl)thio)-3-nitrobenzoate 
• 226259-29-6 methyl 3-amino-4-(2-chloroethylthio)benzoate 
• 67-56-1 methanol 

Relevant articles and documents

SMALL MOLECULE STING ANTAGONISTS

The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis (NASH), pulmonary fibrosis, lupus, sepsis, rheumatoid arthritis (RA), type I diabetes, STING- associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE), retinal vasculopathy, neuroinflammation, systemic inflammatory response syndrome, pancreatitis, cardiovascular disease, renal fibrosis, stroke and age-related macular degeneration (AMD).

Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.